Dr Heather McArthur describes how ASCO 2025 showcased new standards of care in triple-negative and HER2-positive settings.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the ...

In this video, Megan Kruse, MD, breast medical oncologist at Cleveland Clinic, discusses primary results from ASCENT-04 evaluating sacituzumab govitecan plus pembrolizumab in metastatic ...

Pembrolizumab significantly reduced the risk of event free survival events by 30% compared with standard of care.

Cervical cancer prevention advances with new immunotherapy findings, addressing disparities and improving outcomes for ...

Alvotech and Dr. Reddy’s have entered into a collaboration and license agreement to co-develop, manufacture and commercialize ...

Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line treatment significantly reduced the risk of progression or death in patients with ...

In this video, Susana M. Campos, MD, MPH, discusses results from a phase 2 trial of pembrolizumab and lenvatinib for patients with recurrent or persistent clear-cell ovarian cancer.Findings from the ...

A breakthrough study from Keck Medicine of USC may have found a powerful new triple therapy for glioblastoma, one of the ...

Phase 2 study, led by Dr. Antonio Jimeno at the University of Colorado Anschutz Medical Campus will evaluate NT219 in combination with either pembrolizumab or cetuximab as a strategy to ...